EMR P/E Ratio Analysis
Updated 105h ago·SEC filings & market data
Key Takeaway
The current P/E ratio of 30.9x means investors pay $30.90 for every $1 of the company's trailing earnings.
Sector Performance
68th percentileEMR
30.9x
Sector Median
23.1x
Sector Avg
33.7x
Prior Period
32.6x(Aug 2026)
Deep Analysis
The current P/E ratio of 30.9x means investors pay $30.90 for every $1 of the company's trailing earnings.
This is above the sector median of 23.2x, placing EMR at the 68th percentile among sector peers, so it trades at a premium to most comparable companies. The year-over-year change is N/A, while the quarter-over-quarter change is -5.2%, showing the multiple has contracted from 32.6x in the prior quarter. Since the last 8-quarter trend direction is N/A, the only available signal is the recent QoQ decline. A high valuation with a declining trend suggests the premium is easing, which lowers near-term de-rating risk if earnings hold steady. This supports the overall NEUTRAL verdict, as the elevated level is not a bargain, but the recent compression prevents it from being a clear negative.
Frequently Asked Questions
What does the P/E Ratio tell investors about EMR?
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
How is the P/E Ratio calculated?
P/E Ratio is calculated as: Price / EPS.
Who are EMR's closest peers by P/E Ratio?
The closest peers by P/E Ratio include: WELL (102.4x), IAC (104.9x), FORM (108.1x), MCHP (113.5x), MTSI (118.9x).
Learn More About P/E Ratio
The Formula
Price / EPS
Why It Matters
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Master EMR's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full EMR research report →EMR
30.9x
Sector Median
23.1x
Sector Avg
33.7x
How EMR's P/E Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.